TB Archives – Page 14 of 48 – Treatment Action Group

TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris

November 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.

Letter to Special Rapporteur on Cultural Rights

November 9, 2020
Dorrit Walsh

Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her forthcoming communication with the United Nations General Assembly on COVID-19.

Finally—A New Four-Month Treatment for Drug-Susceptible TB!

October 21, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.

Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos

October 21, 2020
Dorrit Walsh

El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.

Research in Action Awards 2020

October 1, 2020
Dorrit Walsh

Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progress and justice.

Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

September 21, 2020
Dorrit Walsh

This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

September 18, 2020
Dorrit Walsh

Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”

Treatment Action Group Condemns Reported Bullying, Harassment, and Racism at Stop TB Partnership

September 13, 2020
Dorrit Walsh

Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.

TB Research Investments Provide Returns in Combating Both TB and COVID-19

September 4, 2020
Dorrit Walsh

As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and…

Demanding a Higher Standard of TB Care

September 2, 2020
Dorrit Walsh

In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.